Drug Profile
Tazemetostat - Epizyme
Alternative Names: Davico; E-7438; EPZ-6438; EZ-438; IPN-60200; Tavico; Tazemetostat hydrobromide - Epizyme; Tazestat - Epizyme; Tazverik; Zestastat - EpizymeLatest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Epizyme
- Developer Eisai Co Ltd; Epizyme; Genentech; HUTCHMED; Ipsen; National Cancer Institute (USA); Pfizer
- Class Amides; Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
- Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors; SMARCA2 protein inhibitors; SMARCA4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Follicular lymphoma; Sarcoma
- Registered Non-Hodgkin's lymphoma
- Phase II CNS cancer; Diffuse large B cell lymphoma; Histiocytosis; Lymphoma; Mesothelioma; Neurofibrosarcoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Rhabdoid tumour; Solid tumours; Synovial sarcoma; Uterine cancer
- Phase I/II Bladder cancer; Non-small cell lung cancer
- No development reported B-cell lymphoma; Mantle-cell lymphoma
Most Recent Events
- 28 Feb 2024 HUTCHMED plans to file NDA for relapsed/refractory Follicular lymphoma expected (second line therapy or greater) in mid-2024 in China
- 11 Dec 2023 Interim efficacy data from the phase-Ib/III SYMPHONY-1 trial in Follicular lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Efficacy and adverse events data from phase I/II trial in Follicular lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)